April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Different Treatment Paradigms of 830 nm Photobiomodulation are Retinoprotective in a Rodent Model of Retinitis Pigmentosa
Author Affiliations & Notes
  • Sandeep Gopalakrishnan
    College of Nursing, University of Wisconsin-Milwaukee, Milwaukee, WI
  • Betsy Abroe
    Biomedical Sciences, University of Wisconsin-Milwaukee, Milwaukee, WI
  • Heather M Schmitt
    Ophthalmology, University of Wisconsin-Madison, Madison, WI
  • Alina Gonzalez-Quevedo
    Biochemistry, Medical Institute of Havana, Havana, Cuba
  • Phyllis Summerfelt
    Ophthalmology, Medical College of Wisconsin, Milwaukee, WI
  • Adam Dubis
    Ophthalmology, University College London, London, United Kingdom
  • Joseph Carroll
    Ophthalmology, Medical College of Wisconsin, Milwaukee, WI
  • Janis T Eells
    Biomedical Sciences, University of Wisconsin-Milwaukee, Milwaukee, WI
  • Footnotes
    Commercial Relationships Sandeep Gopalakrishnan, None; Betsy Abroe, None; Heather Schmitt, None; Alina Gonzalez-Quevedo, None; Phyllis Summerfelt, None; Adam Dubis, None; Joseph Carroll, None; Janis Eells, QBMI Photomedicine (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5760. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sandeep Gopalakrishnan, Betsy Abroe, Heather M Schmitt, Alina Gonzalez-Quevedo, Phyllis Summerfelt, Adam Dubis, Joseph Carroll, Janis T Eells; Different Treatment Paradigms of 830 nm Photobiomodulation are Retinoprotective in a Rodent Model of Retinitis Pigmentosa. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5760.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Previous studies in our laboratory have shown that 830 nm photobiomodulaton (PBM) protects against retinal dysfunction and photoreceptor cell death in the P23H rat model of retinitis pigmentosa when administered early in the course of the disease. The purpose of the present study was to determine if 830 nm PBM would continue to protect against retinal dysfunction and photoreceptor cell death as the animals matured.

Methods: All studies were conducted in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Visual Research. P23H [Line 1] rats were treated once per day with 830 nm light (180 s; 25 mW/cm2; 4.5 J/cm2) using a light-emitting diode array (QDI, Barneveld WI) from [1] postnatal day p10 to p25, [2] p10 to p40 or [3] p20 to p40. Sham-treated rats were restrained for 180 seconds, but not exposed to 830 nm light. Retinal stucture and function was assessed at p30 or p45 by measuring photoreceptor function with electroretinography (ERG), and retinal morphology using spectral domain optical coherence tomography (SD-OCT).

Results: 830nm PBM preserved retinal function and retinal morphology in 830 nm light-treated animals in comparison to the sham-treated group in each treatment protocol. Scotopic full-field flash ERG responses over a range of flash intensities (from 10 to 25000 mcd.s/m2) were greater in 830 nm light-treated P23H rats compared to sham-treated P23H rats. SD-OCT imaging showed that 830 nm PBM also preserved the structural integrity of the retina in each treatment protocol.

Conclusions: Our findings confirm that the retinoprotective effects of 830 PBM observed early in the course of retinal degeneration in the P23H rat persist as the animals mature. Based on our findings and on other studies documenting the neuroprotective actions of PBM in experimental and clinical studies, we propose that photobiomodulation is an innovative, non-invasive therapeutic approach for the treatment of retinal degenerative disease.

Keywords: 695 retinal degenerations: cell biology • 600 mitochondria • 648 photoreceptors  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×